FAS and systemic lupus erythematosus: Although APG101 might be of short-term therapeutic benefit to lupus patients, its inability to discriminate between the anti-tumor/infectious (i.e., apoptotic signaling) and pro-inflammatory actions of CD95 might lead to unexpected adverse events.